Stockreport

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress [Yahoo! Finance]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF Multiple registrational readouts expected across vormatrigine, relutrigine and elsunersen in 2026 Strong balance sheet, with $1.5 billion in pro forma cash and invest [Read more]